Fabry : National Initiative of Screening (FIND)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00484549|
Recruitment Status : Completed
First Posted : June 11, 2007
Last Update Posted : December 21, 2009
Fabry disease is a genetic disease due to an enzymatic deficit. A screening of this disease allows patients to benefit from an enzyme replacement therapy and prevent the occurrence of life threatening manifestations such as an ischemic stroke.
The purpose of the study is to determinate the prevalence of Fabry disease in a population of male patients hospitalized for an ischemic stroke.
This study, with a screening of Fabry disease, allows the patients to make a precise diagnosis of their ischemic stroke and to facilitate the screening of the other members at the facility.
|Condition or disease||Intervention/treatment||Phase|
|Ischemic Stroke Hospitalized||Procedure: Blood sample||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||889 participants|
|Intervention Model:||Single Group Assignment|
|Official Title:||National, Multicenter, Prospective Study of Screening of Fabry Disease in a Population of Men Over 28 Days Old and Less Than 55 Years, Hospitalized for an Ischemic Stroke.|
|Study Start Date :||March 2007|
|Actual Primary Completion Date :||December 2008|
|Actual Study Completion Date :||December 2009|
Procedure: Blood sample
- Fabry disease's screening (Positive microdosage confirmed by a macrodosage) [ Time Frame: Positive microdosage confirmed by a macrodosage ]
- Describe and compare the characteristics of patients affected by Fabry disease and patients who are not affected Identify clinical and neuroradiological predictive elements of Fabry disease [ Time Frame: patients affected by Fabry disease ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00484549
|Hôpital Gabriel Montpied|
|Clermont-Ferrand, France, 63003|
|Principal Investigator:||Pierre Clavelou, Pr||Unaffilliated|